Khalid Halahleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khalid Halahleh has a total of 470 co-authors. Here are the top co-authors by number of shared publications:
Isra Muradi
Al-Ahliyya Amman University (AAU) Al-Salt Jordan
7 shared publications- Hasan Hashem
Division of Pediatric Hematology/Oncology and Bone marrow Transplantation, King Hussein Cancer Center, Amman, Jordan
4 shared publications - Kamal Al-Rabi
Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan
4 shared publications - Mahmoud Aljurf
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
4 shared publications - Mohammad Ma'KOseh
Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan
4 shared publications Rozan Al-Far
Department of Internal Medicine, Adult Bone Marrow Transplantation and Cellular Therapy Program, King Hussein Cancer Center, Amman, Jordan
4 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10108
CD117 as a Lineage-Associated Biomarker in Acute Leukemia: A Favorable Prognostic Marker in AML and an Adverse Predictor in ALL
Acute leukemia comprises heterogeneous hematologic malignancies. CD117 (c-KIT), encoded by the KIT proto-oncogene, is a receptor tyrosine kinase involved in hematopoietic cell survival, proliferation, and differentiation. CD117 expression was assessed in 118 acute myeloid leukemia (AML) and 106 acute lymphoblastic leukemia (ALL) cases and correlated with clinical, immunophenotypic, molecular, and survival parameters. CD117 was expressed in 82.2% of AML and 17.9% of ALL cases. In AML, CD117 positivity was associated with AML-M2 (p < 0.001), core-binding factor (CBF) abnormalities (p = 0.010), and favorable European LeukemiaNet (ELN) 2022 risk (p = 0.041). CD117 independently predicted improved overall survival (OS) in CBF-adjusted (aHR = 0.450, 95% CI: 0.219–0.924, p = 0.030) and ELN-adjusted models (aHR = 0.295, 95% CI: 0.127–0.684, p = 0.004). CD117 was associated with improved event-free survival (EFS) only in the ELN-adjusted model (aHR = 0.374, 95% CI: 0.159–0.882, p = 0.025). In ALL, CD117 was associated with T-cell lineage (p < 0.001) and independently predicted inferior OS (aHR = 4.171, 95% CI: 1.375–12.656, p = 0.012) and EFS (aHR = 3.145, 95% CI: 1.153–8.576, p = 0.025). In T-ALL, it predicted poorer OS (aHR = 3.316, 95% CI: 1.043–10.537, p = 0.042). In conclusion, CD117 has disease-specific prognostic significance, predicting favorable outcomes in AML but adverse outcomes in ALL, particularly T-ALL.
- 11 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10108
Open AccessCD117 as a Lineage-Associated Biomarker in Acute Leukemia: A Favorable Prognostic Marker in AML and an Adverse Predictor in ALL
Acute leukemia comprises heterogeneous hematologic malignancies. CD117 (c-KIT), encoded by the KIT proto-oncogene, is a receptor tyrosine kinase involved in hematopoietic cell survival, proliferation, and differentiation. CD117 expression was assessed in 118 acute myeloid leukemia (AML) and 106 acute lymphoblastic leukemia (ALL) cases and correlated with clinical, immunophenotypic, molecular, and survival parameters. CD117 was expressed in 82.2% of AML and 17.9% of ALL cases. In AML, CD117 positivity was associated with AML-M2 (p < 0.001), core-binding factor (CBF) abnormalities (p = 0.010), and favorable European LeukemiaNet (ELN) 2022 risk (p = 0.041). CD117 independently predicted improved overall survival (OS) in CBF-adjusted (aHR = 0.450, 95% CI: 0.219–0.924, p = 0.030) and ELN-adjusted models (aHR = 0.295, 95% CI: 0.127–0.684, p = 0.004). CD117 was associated with improved event-free survival (EFS) only in the ELN-adjusted model (aHR = 0.374, 95% CI: 0.159–0.882, p = 0.025). In ALL, CD117 was associated with T-cell lineage (p < 0.001) and independently predicted inferior OS (aHR = 4.171, 95% CI: 1.375–12.656, p = 0.012) and EFS (aHR = 3.145, 95% CI: 1.153–8.576, p = 0.025). In T-ALL, it predicted poorer OS (aHR = 3.316, 95% CI: 1.043–10.537, p = 0.042). In conclusion, CD117 has disease-specific prognostic significance, predicting favorable outcomes in AML but adverse outcomes in ALL, particularly T-ALL.
- Open Access
- 30 September 2026
- Published by Springer Nature in Bone Marrow Transplantation
- p. 1-8
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party
Myelodysplastic syndromes (MDS) in young adults are uncommon and underrepresented in transplant cohorts. We evaluated 697 patients aged 18–40 years who underwent first allogeneic hematopoietic cell transplantation (allo-HCT) reported to the EBMT between 2016 and 2021. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and graft-versus-host disease (GVHD). With a median follow-up of 2.8 years, 3-year OS and PFS were 69% (95% CI, 65–73) and 62% (58–66), respectively. At 3 years, CIR and NRM were 20% (16–23) and 18% (15–21). Grade II–IV acute GVHD occurred in 28% (25–32) by day +100, while chronic GVHD and extensive chronic GVHD occurred in 38% (34–42) and 18% (14–21) at 3 years. In multivariable analysis, very-poor cytogenetic risk was associated with inferior OS (HR 2.81, 95% CI 1.77–4.45). Haploidentical donors and reduced-intensity conditioning were also associated with inferior survival. Patients younger than 30 years had superior PFS, whereas outcomes with matched sibling and matched unrelated donors were comparable. These findings support the feasibility of allo-HCT in young adults with MDS and may help inform risk-adapted transplant approaches.
- 30 September 2026
- Published by Springer Nature in Bone Marrow Transplantation
- p. 1-8
Open AccessAllogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party
Myelodysplastic syndromes (MDS) in young adults are uncommon and underrepresented in transplant cohorts. We evaluated 697 patients aged 18–40 years who underwent first allogeneic hematopoietic cell transplantation (allo-HCT) reported to the EBMT between 2016 and 2021. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and graft-versus-host disease (GVHD). With a median follow-up of 2.8 years, 3-year OS and PFS were 69% (95% CI, 65–73) and 62% (58–66), respectively. At 3 years, CIR and NRM were 20% (16–23) and 18% (15–21). Grade II–IV acute GVHD occurred in 28% (25–32) by day +100, while chronic GVHD and extensive chronic GVHD occurred in 38% (34–42) and 18% (14–21) at 3 years. In multivariable analysis, very-poor cytogenetic risk was associated with inferior OS (HR 2.81, 95% CI 1.77–4.45). Haploidentical donors and reduced-intensity conditioning were also associated with inferior survival. Patients younger than 30 years had superior PFS, whereas outcomes with matched sibling and matched unrelated donors were comparable. These findings support the feasibility of allo-HCT in young adults with MDS and may help inform risk-adapted transplant approaches.
- 27 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2786-2798
Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)
Baseline IPSS‐M risk, response to hypomethylating agent (HMA) therapy, and receipt of allogeneic stem cell transplant (allo‐HCT) have all been individually shown to impact overall survival (OS) in patients with myelodysplastic syndromes (MDS). However, the prognostic impact of response when adjusting for IPSS‐M risk and treatment strategy remains unclear. Hence, we used the VALIDATE database of the International Consortium for MDS (icMDS) to evaluate the impact of International Working Group (IWG) 2023 best response on OS in 715 HMA‐treated, higher‐risk MDS patients stratified by baseline IPSS‐M risk and their treatment strategy (subsequent allo‐HCT vs. medical therapy alone) treating both best response and allo‐HCT as time‐dependent variables. Baseline IPSS‐M risk (hazard ratio (HR): 0.5, p < 0.001) and receipt of allo‐HCT (HR: 0.5, p < 0.001) were the strongest independent predictors of OS, whereas achievement of composite complete response (cCR) had a more modest impact on OS (HR: 0.8, p = 0.004). Among patients treated with medical therapy alone, achieving cCR improved OS significantly (HR: 0.7, p = 0.006). In contrast, among transplanted patients, cCR did not retain independent prognostic value for post‐transplant survival after adjusting for baseline IPSS‐M (HR: 0.9, p = 0.634). Achieving cCR did not fully overcome adverse disease biology as OS continued to segregate according to baseline IPSS‐M risk. In summary, achieving cCR improves outcomes in non‐transplanted patients, but it does not significantly impact post‐transplant OS, suggesting that failure to achieve cCR with HMA may not warrant delay or preclude allo‐HCT. Clinical trials should consider response in the context of IPSS‐M risk distribution and treatment strategy (subsequent allo‐HCT vs. medical therapy alone) to avoid overinterpretation of high response rates.
- 27 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2786-2798
Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)
Baseline IPSS‐M risk, response to hypomethylating agent (HMA) therapy, and receipt of allogeneic stem cell transplant (allo‐HCT) have all been individually shown to impact overall survival (OS) in patients with myelodysplastic syndromes (MDS). However, the prognostic impact of response when adjusting for IPSS‐M risk and treatment strategy remains unclear. Hence, we used the VALIDATE database of the International Consortium for MDS (icMDS) to evaluate the impact of International Working Group (IWG) 2023 best response on OS in 715 HMA‐treated, higher‐risk MDS patients stratified by baseline IPSS‐M risk and their treatment strategy (subsequent allo‐HCT vs. medical therapy alone) treating both best response and allo‐HCT as time‐dependent variables. Baseline IPSS‐M risk (hazard ratio (HR): 0.5, p < 0.001) and receipt of allo‐HCT (HR: 0.5, p < 0.001) were the strongest independent predictors of OS, whereas achievement of composite complete response (cCR) had a more modest impact on OS (HR: 0.8, p = 0.004). Among patients treated with medical therapy alone, achieving cCR improved OS significantly (HR: 0.7, p = 0.006). In contrast, among transplanted patients, cCR did not retain independent prognostic value for post‐transplant survival after adjusting for baseline IPSS‐M (HR: 0.9, p = 0.634). Achieving cCR did not fully overcome adverse disease biology as OS continued to segregate according to baseline IPSS‐M risk. In summary, achieving cCR improves outcomes in non‐transplanted patients, but it does not significantly impact post‐transplant OS, suggesting that failure to achieve cCR with HMA may not warrant delay or preclude allo‐HCT. Clinical trials should consider response in the context of IPSS‐M risk distribution and treatment strategy (subsequent allo‐HCT vs. medical therapy alone) to avoid overinterpretation of high response rates.
- 11 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Anaphylactic reaction to the second dose of dacarbazine following initial exposure in patient with hodgkin lymphoma
Introduction: Dacarbazine is generally well-tolerated, apart from its hematologic toxicities; however, rare and life-threatening anaphylactic reactions have been reported. We aimed to describe a rare case of anaphylactic reaction to dacarbazine following a previously tolerated first dose. Case Report: We report a case of a 69-year-old male patient with classical Hodgkin lymphoma, who was planned for nivolumab, doxorubicin, vinblastine, and dacarbazine (N + AVD) combination, day 1 and 15 every 28 days. The patient received day 1 of cycle#1, without any complications. On day 15, the patient developed a severe anaphylactic reaction 5 min after the start of dacarbazine infusion. The reaction was manifested by hypoxia, shivering, itching, and laryngeal edema. Management & Outcome: Patient required immediate interruption of dacarbazine infusion and received 10 mg of intravenous chlorphenamine and 200 mg of intravenous hydrocortisone initially with no improvement. Hypoxia and laryngeal edema improved following the administration of 0.3 mg intramuscular epinephrine. The patient was transferred to the intensive care unit for close monitoring due to increased risk of biphasic anaphylactic reaction, in which symptoms can recur after initial resolution. Oxygen saturation improved from 82% to 90–93%, and the patient remained hemodynamically stable without complications. Dacarbazine was discontinued. Patient continued nivolumab, doxorubicin, and vinblastine (N + AV) for five cycles, and achieved complete metabolic response. Discussion: This case highlights that anaphylactic reaction to dacarbazine may occur despite prior tolerance to the first dose. Physicians should suspect reaction during subsequent infusions of dacarbazine, even when initial cycle is tolerated.
- 11 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Anaphylactic reaction to the second dose of dacarbazine following initial exposure in patient with hodgkin lymphoma
Introduction: Dacarbazine is generally well-tolerated, apart from its hematologic toxicities; however, rare and life-threatening anaphylactic reactions have been reported. We aimed to describe a rare case of anaphylactic reaction to dacarbazine following a previously tolerated first dose. Case Report: We report a case of a 69-year-old male patient with classical Hodgkin lymphoma, who was planned for nivolumab, doxorubicin, vinblastine, and dacarbazine (N + AVD) combination, day 1 and 15 every 28 days. The patient received day 1 of cycle#1, without any complications. On day 15, the patient developed a severe anaphylactic reaction 5 min after the start of dacarbazine infusion. The reaction was manifested by hypoxia, shivering, itching, and laryngeal edema. Management & Outcome: Patient required immediate interruption of dacarbazine infusion and received 10 mg of intravenous chlorphenamine and 200 mg of intravenous hydrocortisone initially with no improvement. Hypoxia and laryngeal edema improved following the administration of 0.3 mg intramuscular epinephrine. The patient was transferred to the intensive care unit for close monitoring due to increased risk of biphasic anaphylactic reaction, in which symptoms can recur after initial resolution. Oxygen saturation improved from 82% to 90–93%, and the patient remained hemodynamically stable without complications. Dacarbazine was discontinued. Patient continued nivolumab, doxorubicin, and vinblastine (N + AV) for five cycles, and achieved complete metabolic response. Discussion: This case highlights that anaphylactic reaction to dacarbazine may occur despite prior tolerance to the first dose. Physicians should suspect reaction during subsequent infusions of dacarbazine, even when initial cycle is tolerated.
- 17 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (10) , 1343-1352
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
The optimal myeloablative conditioning regimen for adolescents and young adults with acute myeloid leukaemia (AML) is currently unknown. In this retrospective analysis conducted on AML patients aged 18-40 years, in complete remission (CR), who received an allogeneic hematopoietic cell transplantation (HCT) we compared outcomes of different conditioning regimens. A total of 4323 patients, with median age of 30.9 years, transplanted from 2010 to 2022, received one of four regimens: high-dose total body irradiation (TBI)-based (n = 1031), thiotepa-busulfan (Bu)-fludarabine (Flu) (TBF) n = 219, Bu-Flu (n = 1100), and Bu-cyclophosphamide (Cy) (n = 1973). Prolonged OS and PFS for Bu-Flu (hazard ratio [HR] 0.73, 95% CI 0.57-0.92, p = 0.008; HR 0.78, 95% CI 0.64-0.94, p = 0.01), and TBF (HR 0.59, 95% CI 0.38-0.92, p = 0.02; HR 0.67, 95% CI 0.47-0.94, p = 0.02), respectively, as well as less RI for both Bu-Flu (HR 0.77, 95% CI 0.63-0.95, p = 0.01), and TBF (HR 0.68, 95% CI 0.47-0.99, p = 0.046). In conclusion, young adult AML patients seem to benefit from high dose TBI-free regimens, in terms of survival and toxicity, with four major myeloablative regimens. TBF and Bu-Flu were associated with better clinical outcomes, partly reflecting the general improvement in supportive therapies and patient selection introduced in recent years. Prospective clinical trials are warranted.
- 17 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (10) , 1343-1352
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
The optimal myeloablative conditioning regimen for adolescents and young adults with acute myeloid leukaemia (AML) is currently unknown. In this retrospective analysis conducted on AML patients aged 18-40 years, in complete remission (CR), who received an allogeneic hematopoietic cell transplantation (HCT) we compared outcomes of different conditioning regimens. A total of 4323 patients, with median age of 30.9 years, transplanted from 2010 to 2022, received one of four regimens: high-dose total body irradiation (TBI)-based (n = 1031), thiotepa-busulfan (Bu)-fludarabine (Flu) (TBF) n = 219, Bu-Flu (n = 1100), and Bu-cyclophosphamide (Cy) (n = 1973). Prolonged OS and PFS for Bu-Flu (hazard ratio [HR] 0.73, 95% CI 0.57-0.92, p = 0.008; HR 0.78, 95% CI 0.64-0.94, p = 0.01), and TBF (HR 0.59, 95% CI 0.38-0.92, p = 0.02; HR 0.67, 95% CI 0.47-0.94, p = 0.02), respectively, as well as less RI for both Bu-Flu (HR 0.77, 95% CI 0.63-0.95, p = 0.01), and TBF (HR 0.68, 95% CI 0.47-0.99, p = 0.046). In conclusion, young adult AML patients seem to benefit from high dose TBI-free regimens, in terms of survival and toxicity, with four major myeloablative regimens. TBF and Bu-Flu were associated with better clinical outcomes, partly reflecting the general improvement in supportive therapies and patient selection introduced in recent years. Prospective clinical trials are warranted.
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500648
Point-of-Care Manufacturing of Anti–CD19.1-Chimeric Antigen Receptor-T Cells Using CliniMACS Prodigy: Real-World Experience From Jordan
PURPOSE: Industry-driven chimeric antigen receptor (CAR)-T cell manufacturing is complex and time-consuming. We hypothesized that decentralized manufacturing of CAR-T cells on an automated closed CliniMACS Prodigy system (Miltenyi Biotec) is feasible and reproducible for patients with relapsed refractory non-Hodgkin's lymphoma (rrNHL) in a developing country. MATERIALS AND METHODS: To manufacture anti–MB-19.1-CAR-T cell products, peripheral blood mononuclear cells were collected, enriched into pure T cells by positive selection using CD4 and CD8 magnetic beads, redirected into the chamber of the CliniMACS Prodigy for activation with the T-cell TransAct reagent containing CD3 and CD28, followed by transduction by anti–MB-CD19.1-CAR Lentiviral Vector, and cultured for 12 days followed by cell harvesting. Eleven products were manufactured, three from healthy donors for feasibility evaluation and eight clinical-grade products under a phase II clinical trial. Quality control and release manufacturer standards were set to ensure their identity, viability, purity, sterility, and potency. RESULTS: Eleven anti–CD19.1-CAR-T products with reproducible key characteristics were manufactured. Validation run data demonstrated a successful anti–CD19.1-CAR-T cell production with 51-fold T-cell expansion, a robust transduction efficiency of 26%, a viability of 98%, and fulfillment of manufacturer standards for clinical application. Clinical-grade products demonstrated 35-fold T-cell expansion, 44% transduction efficiency, and 99.8% viability, and fulfilling quality checks. The average vein-to-vein time is 15.25 days (range, 15-17). Safety and efficacy of clinical-grade products in the first eight patients enrolled showed reasonable objective responses with no new safety signals. CONCLUSION: Our data highlight the feasibility and reproducibility of the point of care of anti–CD19.1-CAR-T cells in a developing country, Jordan.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500648
Open AccessPoint-of-Care Manufacturing of Anti–CD19.1-Chimeric Antigen Receptor-T Cells Using CliniMACS Prodigy: Real-World Experience From Jordan
PURPOSE: Industry-driven chimeric antigen receptor (CAR)-T cell manufacturing is complex and time-consuming. We hypothesized that decentralized manufacturing of CAR-T cells on an automated closed CliniMACS Prodigy system (Miltenyi Biotec) is feasible and reproducible for patients with relapsed refractory non-Hodgkin's lymphoma (rrNHL) in a developing country. MATERIALS AND METHODS: To manufacture anti–MB-19.1-CAR-T cell products, peripheral blood mononuclear cells were collected, enriched into pure T cells by positive selection using CD4 and CD8 magnetic beads, redirected into the chamber of the CliniMACS Prodigy for activation with the T-cell TransAct reagent containing CD3 and CD28, followed by transduction by anti–MB-CD19.1-CAR Lentiviral Vector, and cultured for 12 days followed by cell harvesting. Eleven products were manufactured, three from healthy donors for feasibility evaluation and eight clinical-grade products under a phase II clinical trial. Quality control and release manufacturer standards were set to ensure their identity, viability, purity, sterility, and potency. RESULTS: Eleven anti–CD19.1-CAR-T products with reproducible key characteristics were manufactured. Validation run data demonstrated a successful anti–CD19.1-CAR-T cell production with 51-fold T-cell expansion, a robust transduction efficiency of 26%, a viability of 98%, and fulfillment of manufacturer standards for clinical application. Clinical-grade products demonstrated 35-fold T-cell expansion, 44% transduction efficiency, and 99.8% viability, and fulfilling quality checks. The average vein-to-vein time is 15.25 days (range, 15-17). Safety and efficacy of clinical-grade products in the first eight patients enrolled showed reasonable objective responses with no new safety signals. CONCLUSION: Our data highlight the feasibility and reproducibility of the point of care of anti–CD19.1-CAR-T cells in a developing country, Jordan.
- Open Access
- 29 June 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database
Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed HR-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated. We analyzed 1907 patients with HR-MDS from 31 centers in 9 countries who were treated with HMA monotherapy or HMA/VEN in the frontline setting (HMA monotherapy: n = 1773; HMA/VEN: n = 134). Responses were assessed centrally by two investigators using the IWG 2023 response criteria. Addition of VEN improved composite complete remission (cCR) rates (48.8% vs. 27.7%; p < 0.001) but not CR rates (17.1% vs. 11.7%; p = 0.16). In multivariable logistic regression analysis, cCR remained favorable for HMA/VEN vs. HMA monotherapy (Odds Ratio [OR]: 2.49; 95% CI: 1.56-3.96; p < 0.001). However, we did not observe a statistically significant difference in OS for HMA/VEN vs. HMA monotherapy (Hazard Ratio [HR]: 0.83; 95% CI: 0.64-1.07; p = 0.15). In subgroup analyses, patients with TP53 wild-type disease (HR: 0.47; 95% CI: 0.29-0.74; p = 0.002) had a significant improvement in OS and those with ≥10% bone marrow blasts (HR: 0.73; 95% CI: 0.53-1.01; p = 0.06) had a trend towards OS benefit with HMA/VEN.
- 29 June 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessOutcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database
Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed HR-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated. We analyzed 1907 patients with HR-MDS from 31 centers in 9 countries who were treated with HMA monotherapy or HMA/VEN in the frontline setting (HMA monotherapy: n = 1773; HMA/VEN: n = 134). Responses were assessed centrally by two investigators using the IWG 2023 response criteria. Addition of VEN improved composite complete remission (cCR) rates (48.8% vs. 27.7%; p < 0.001) but not CR rates (17.1% vs. 11.7%; p = 0.16). In multivariable logistic regression analysis, cCR remained favorable for HMA/VEN vs. HMA monotherapy (Odds Ratio [OR]: 2.49; 95% CI: 1.56-3.96; p < 0.001). However, we did not observe a statistically significant difference in OS for HMA/VEN vs. HMA monotherapy (Hazard Ratio [HR]: 0.83; 95% CI: 0.64-1.07; p = 0.15). In subgroup analyses, patients with TP53 wild-type disease (HR: 0.47; 95% CI: 0.29-0.74; p = 0.002) had a significant improvement in OS and those with ≥10% bone marrow blasts (HR: 0.73; 95% CI: 0.53-1.01; p = 0.06) had a trend towards OS benefit with HMA/VEN.